Trial Profile
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients With MDS
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 21 Mar 2023 Planned End Date changed from 30 Nov 2022 to 6 Nov 2023.
- 29 Jun 2022 Planned primary completion date changed from 30 Nov 2021 to 30 Nov 2022.
- 02 Sep 2021 "Incidence of adverse events" has been removed from the primary end-points, thus removing "AR" as the trial focus.